Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 427

1.

Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data.

Grams ME, Sang Y, Ballew SH, Matsushita K, Astor BC, Carrero JJ, Chang AR, Inker LA, Kenealy T, Kovesdy CP, Lee BJ, Levin A, Naimark D, Pena MJ, Schold JD, Shalev V, Wetzels JFM, Woodward M, Gansevoort RT, Levey AS, Coresh J.

J Am Soc Nephrol. 2019 Jul 10. pii: ASN.2019010008. doi: 10.1681/ASN.2019010008. [Epub ahead of print]

PMID:
31292199
2.

Performance of GFR Slope as a Surrogate Endpoint for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.

Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker LA.

J Am Soc Nephrol. 2019 Jul 10. pii: ASN.2019010009. doi: 10.1681/ASN.2019010009. [Epub ahead of print]

PMID:
31292198
3.

The authors reply.

van de Logt AE, Rijpma SR, Vink CH, Prudon-Rosmulder E, Wetzels JF, van Berkel M.

Kidney Int. 2019 Jul;96(1):249. doi: 10.1016/j.kint.2019.04.008. No abstract available.

PMID:
31229039
4.

The bias between different albumin assays may affect clinical decision-making.

van de Logt AE, Rijpma SR, Vink CH, Prudon-Rosmulder E, Wetzels JF, van Berkel M.

Kidney Int. 2019 Jun;95(6):1514-1517. doi: 10.1016/j.kint.2019.01.042. Epub 2019 Feb 27.

PMID:
31053386
5.

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH; DIPAK-1 Investigators.

Gastroenterology. 2019 Apr 22. pii: S0016-5085(19)36711-3. doi: 10.1053/j.gastro.2019.04.018. [Epub ahead of print]

PMID:
31022403
6.

Placental passage of eculizumab and complement blockade in a newborn.

Duineveld C, Wijnsma KL, Volokhina EB, van den Heuvel LPB, van de Kar NCAJ, Wetzels JFM.

Kidney Int. 2019 Apr;95(4):996. doi: 10.1016/j.kint.2019.01.012. No abstract available.

PMID:
30904074
7.

Assessment of Plasma Resistivity as a Surrogate for Extracellular Fluid Resistivity: Analytical Performance and Impact of Fluid Composition.

Schotman JM, van Borren MMGJ, Wetzels JFM, Kloke HJ, Reichert LJM, de Boer H.

Ann Biomed Eng. 2019 Jun;47(6):1463-1469. doi: 10.1007/s10439-019-02246-9. Epub 2019 Mar 19.

PMID:
30891658
8.

Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.

Zaghrini C, Seitz-Polski B, Justino J, Dolla G, Payré C, Jourde-Chiche N, Van de Logt AE, Booth C, Rigby E, Lonnbro-Widgren J, Nystrom J, Mariat C, Cui Z, Wetzels JFM, Ghiggeri G, Beck LH Jr, Ronco P, Debiec H, Lambeau G.

Kidney Int. 2019 Mar;95(3):666-679. doi: 10.1016/j.kint.2018.10.024.

PMID:
30784662
9.

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ.

Clin Pharmacokinet. 2019 Jul;58(7):859-874. doi: 10.1007/s40262-019-00742-8. Review.

10.

NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor.

Boulangé CL, Rood IM, Posma JM, Lindon JC, Holmes E, Wetzels JFM, Deegens JKJ, Kaluarachchi MR.

Mol Omics. 2019 Feb 11;15(1):39-49. doi: 10.1039/c8mo00190a.

PMID:
30672550
11.

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH; Conference Participants.

Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018.

PMID:
30665568
12.

Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ.

Pediatr Nephrol. 2019 Apr;34(4):741-742. doi: 10.1007/s00467-018-4186-x.

13.

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.

Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8.

PMID:
30635225
14.

Antibodies Against M-Type Phospholipase Receptor and Prediction of Outcome in Membranous Nephropathy: We are Not There Yet.

Wetzels JFM.

Am J Nephrol. 2018;48(6):434-437. doi: 10.1159/000494661. Epub 2018 Nov 23. No abstract available.

15.

Progressive kidney failure in chronic myelomonocytic leukaemia: don't forget lysozyme damage.

Hillen JM, Raemaekers JM, Steenbergen EJ, Wetzels JFM, Verhave JC.

Neth J Med. 2018 Nov;76(9):407-410.

16.

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT; DIPAK-1 Investigators.

JAMA. 2018 Nov 20;320(19):2010-2019. doi: 10.1001/jama.2018.15870.

17.

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C.

Nephrol Dial Transplant. 2018 Nov 9. doi: 10.1093/ndt/gfy302. [Epub ahead of print]

PMID:
30418652
18.

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ.

Pediatr Nephrol. 2018 Nov 6. doi: 10.1007/s00467-018-4091-3. [Epub ahead of print] Review. Erratum in: Pediatr Nephrol. 2019 Jan 15;:.

PMID:
30402748
19.

The Use of N-of-1 Trials to Individualize Treatment in Patients With Renal Magnesium Wasting.

Bech AP, Wetzels JFM, Groenewoud H, Nijenhuis T.

Am J Kidney Dis. 2019 Feb;73(2):288-290. doi: 10.1053/j.ajkd.2018.08.010. Epub 2018 Oct 11. No abstract available.

PMID:
30318133
20.

Urine Acidification After Ammonium Chloride.

Bech AP, Nijenhuis T, Wetzels JFM.

Am J Kidney Dis. 2018 Dec;72(6):909-911. doi: 10.1053/j.ajkd.2018.07.018. Epub 2018 Oct 5. No abstract available.

PMID:
30297083
21.

Nephrotic Syndrome With Mutations in NPHS2: The Role of R229Q and Implications for Genetic Counseling.

Rood IM, Deegens JKJ, Lugtenberg D, Bongers EMHF, Wetzels JFM.

Am J Kidney Dis. 2019 Mar;73(3):400-403. doi: 10.1053/j.ajkd.2018.06.034. Epub 2018 Sep 18.

PMID:
30241959
22.

Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy.

Duineveld C, van de Kar NCAJ, Wetzels JFM.

Am J Kidney Dis. 2018 Dec;72(6):906. doi: 10.1053/j.ajkd.2018.07.013. Epub 2018 Sep 17. No abstract available.

PMID:
30236630
23.

Yield of diagnostic tests in unexplained renal hypophosphatemia: a case series.

Bech AP, Hoorn EJ, Zietse R, Wetzels JFM, Nijenhuis T.

BMC Nephrol. 2018 Sep 4;19(1):220. doi: 10.1186/s12882-018-1017-z.

24.

What Patients with Mild-to-Moderate Kidney Disease Know, Think, and Feel about Their Disease: An In-Depth Interview Study.

van Dipten C, de Grauw WJC, Wetzels JFM, Assendelft WJJ, Scherpbier-de Haan ND, Dees MK.

J Am Board Fam Med. 2018 Jul-Aug;31(4):570-577. doi: 10.3122/jabfm.2018.04.170459.

25.

The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury.

Verheijden KAT, Sonneveld R, Bakker-van Bebber M, Wetzels JFM, van der Vlag J, Nijenhuis T.

J Am Soc Nephrol. 2018 Aug;29(8):2099-2109. doi: 10.1681/ASN.2016111248. Epub 2018 Jun 28.

PMID:
29954830
26.

General practitioners' perspectives on management of early-stage chronic kidney disease: a focus group study.

van Dipten C, van Berkel S, de Grauw WJC, Scherpbier-de Haan ND, Brongers B, van Spaendonck K, Wetzels JFM, Assendelft WJJ, Dees MK.

BMC Fam Pract. 2018 Jun 6;19(1):81. doi: 10.1186/s12875-018-0736-3.

27.

Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers.

Bech AP, Wetzels JFM, Nijenhuis T.

Physiol Rep. 2018 Apr;6(7):e13665. doi: 10.14814/phy2.13665.

28.

CD44 is required for the pathogenesis of experimental crescentic glomerulonephritis and collapsing focal segmental glomerulosclerosis.

Eymael J, Sharma S, Loeven MA, Wetzels JF, Mooren F, Florquin S, Deegens JK, Willemsen BK, Sharma V, van Kuppevelt TH, Bakker MA, Ostendorf T, Moeller MJ, Dijkman HB, Smeets B, van der Vlag J.

Kidney Int. 2018 Mar;93(3):626-642. doi: 10.1016/j.kint.2017.09.020. Epub 2017 Dec 21.

PMID:
29276101
29.

Reference values of renal tubular function tests are dependent on age and kidney function.

Bech AP, Wetzels JFM, Nijenhuis T.

Physiol Rep. 2017 Dec;5(23). doi: 10.14814/phy2.13542.

30.

Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.

Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM.

Nephrol Dial Transplant. 2018 Apr 1;33(4):635-645. doi: 10.1093/ndt/gfx196.

PMID:
29106598
31.

Renal physiology: Prostaglandins in thiazide-induced hyponatraemia: do they hold water?

Hoorn EJ, Wetzels JFM.

Nat Rev Nephrol. 2017 Nov;13(11):665-666. doi: 10.1038/nrneph.2017.133. Epub 2017 Sep 25. No abstract available.

PMID:
28944774
32.

The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.

D'Agnolo HMA, Casteleijn NF, Gevers TJG, de Fijter H, van Gastel MDA, Messchendorp AL, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JFM, Zietse R, Gansevoort RT, Drenth JPH.

Am J Nephrol. 2017;46(3):239-248. doi: 10.1159/000479436. Epub 2017 Sep 8.

PMID:
28881341
33.

Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.

Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.

Am J Kidney Dis. 2017 Dec;70(6):770-777. doi: 10.1053/j.ajkd.2017.06.024. Epub 2017 Aug 16.

PMID:
28821363
34.

A Novel Hypokalemic-Alkalotic Salt-Losing Tubulopathy in Patients with CLDN10 Mutations.

Bongers EMHF, Shelton LM, Milatz S, Verkaart S, Bech AP, Schoots J, Cornelissen EAM, Bleich M, Hoenderop JGJ, Wetzels JFM, Lugtenberg D, Nijenhuis T.

J Am Soc Nephrol. 2017 Oct;28(10):3118-3128. doi: 10.1681/ASN.2016080881. Epub 2017 Jul 3.

35.

Disposition and clinical implications of protein-bound uremic toxins.

Jansen J, Jankowski J, Gajjala PR, Wetzels JFM, Masereeuw R.

Clin Sci (Lond). 2017 Jun 30;131(14):1631-1647. doi: 10.1042/CS20160191. Print 2017 Jul 15. Review.

PMID:
28667064
36.

Use of the Furosemide Fludrocortisone Test to Clinically Assess Distal Tubular Acidification.

Bech AP, Wetzels JFM, Nijenhuis T.

Am J Kidney Dis. 2017 Oct;70(4):589-591. doi: 10.1053/j.ajkd.2017.05.009. Epub 2017 Jun 17. No abstract available.

PMID:
28634085
37.

Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability.

de Groot T, Doornebal J, Christensen BM, Cockx S, Sinke AP, Baumgarten R, Bedford JJ, Walker RJ, Wetzels JFM, Deen PMT.

Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F669-F676. doi: 10.1152/ajprenal.00147.2017. Epub 2017 Jun 14.

38.

Urinary Excretion of α1-Microglobulin Does Not Predict Graft Loss in Stable Kidney Transplant Recipients.

Bech AP, Hoogendijk JM, Wetzels JF.

Am J Kidney Dis. 2017 Jul;70(1):151. doi: 10.1053/j.ajkd.2017.02.377. Epub 2017 May 10. No abstract available.

PMID:
28501240
39.

Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

van den Brand JAJG, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G.

J Am Soc Nephrol. 2017 Sep;28(9):2729-2737. doi: 10.1681/ASN.2016091022. Epub 2017 May 9.

40.

Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.

van den Brand JA, Verhave JC, Adang EM, Wetzels JF.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i115-i122. doi: 10.1093/ndt/gfw353.

PMID:
28391343
41.

Adherence to chronic kidney disease guidelines in primary care patients is associated with comorbidity.

van Dipten C, van Berkel S, van Gelder VA, Wetzels JFM, Akkermans RP, de Grauw WJC, Biermans MCJ, Scherpbier-de Haan ND, Assendelft WJJ.

Fam Pract. 2017 Aug 1;34(4):459-466. doi: 10.1093/fampra/cmx002.

PMID:
28207923
42.

Web-based consultation between general practitioners and nephrologists: a cluster randomized controlled trial.

van Gelder VA, Scherpbier-de Haan ND, van Berkel S, Akkermans RP, de Grauw IS, Adang EM, Assendelft PJ, de Grauw WJC, Biermans MCJ, Wetzels JFM.

Fam Pract. 2017 Aug 1;34(4):430-436. doi: 10.1093/fampra/cmw131.

PMID:
28158576
43.

Glomerular disease in 2016: New advances in the treatment of glomerular disease.

Maas RJ, Wetzels JF.

Nat Rev Nephrol. 2017 Jan 19;13(2):65-66. doi: 10.1038/nrneph.2016.195. No abstract available.

PMID:
28100906
44.

The Clinical Course of Minimal Change Nephrotic Syndrome With Onset in Adulthood or Late Adolescence: A Case Series.

Maas RJ, Deegens JK, Beukhof JR, Reichert LJ, Ten Dam MA, Beutler JJ, van den Wall Bake AWL, Rensma PL, Konings CJ, Geerse DA, Feith GW, Van Kuijk WH, Wetzels JF.

Am J Kidney Dis. 2017 May;69(5):637-646. doi: 10.1053/j.ajkd.2016.10.032. Epub 2017 Jan 12.

PMID:
28089478
45.

Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients.

Zittema D, van den Brand JA, Bakker SJ, Wetzels JF, Gansevoort RT.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i146-i153. doi: 10.1093/ndt/gfw391.

PMID:
28057871
46.

Uremic Solutes in Chronic Kidney Disease and Their Role in Progression.

van den Brand JA, Mutsaers HA, van Zuilen AD, Blankestijn PJ, van den Broek PH, Russel FG, Masereeuw R, Wetzels JF.

PLoS One. 2016 Dec 29;11(12):e0168117. doi: 10.1371/journal.pone.0168117. eCollection 2016.

47.

Lifetime risk of renal replacement therapy in Europe: a population-based study using data from the ERA-EDTA Registry.

van den Brand JAJG, Pippias M, Stel VS, Caskey FJ, Collart F, Finne P, Heaf J, Jais JP, Kramar R, Massy ZA, De Meester J, Traynor JP, Reisæter AV, Wetzels JFM, Jager KJ.

Nephrol Dial Transplant. 2017 Feb 1;32(2):348-355. doi: 10.1093/ndt/gfw392.

PMID:
28031344
48.

Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.

Lantinga MA, D'Agnolo HM, Casteleijn NF, de Fijter JW, Meijer E, Messchendorp AL, Peters DJ, Salih M, Spithoven EM, Soonawala D, Visser FW, Wetzels JF, Zietse R, Drenth JP, Gansevoort RT; DIPAK Consortium.

Drug Saf. 2017 Feb;40(2):153-167. doi: 10.1007/s40264-016-0486-x.

49.

Minimal change disease and idiopathic FSGS: manifestations of the same disease.

Maas RJ, Deegens JK, Smeets B, Moeller MJ, Wetzels JF.

Nat Rev Nephrol. 2016 Dec;12(12):768-776. doi: 10.1038/nrneph.2016.147. Epub 2016 Oct 17. Review.

PMID:
27748392
50.

Drug therapy management in patients with renal impairment: how to use creatinine-based formulas in clinical practice.

Eppenga WL, Kramers C, Derijks HJ, Wensing M, Wetzels JF, De Smet PA.

Eur J Clin Pharmacol. 2016 Dec;72(12):1433-1439. Epub 2016 Aug 27.

Supplemental Content

Loading ...
Support Center